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Background: The identiﬁcation of the best strategy to manage cytomegalovirus infection is
hampered by uncertainties regarding the risk/beneﬁt ratios of universal prophylaxis versus
preemptive therapy, the impact of indirect cytomegalovirus effects and the associated costs.
This  study investigated the efﬁcacy and safety of targeted preemptive therapy according to
perceived risk of cytomegalovirus infection after kidney transplantation.
Methods: 144 adult kidney transplant recipients were enrolled in this 12-month study. None
received cytomegalovirus pharmacological prophylaxis. Only high risk patients (positive
donor/negative recipient (D+/R−), use of induction therapy with antithymocyte globulin,
treatment of rejection) received preemptive therapy based on the result of pp65 antigen-
emia test. Low-risk patients with symptoms related to cytomegalovirus were screened for
pp65 antigenemia and treatment initiated if conﬁrmed cytomegalovirus disease. Blinded
cytomegalovirus DNAemia was collected weekly during the ﬁrst three months.
Results: The incidence of cytomegalovirus infection was 34% and cytomegalovirus disease
was 17%. The incidence was 25% in D+/R−, 69% in those receiving induction with rabbit
antithymocite globulin (r-ATG), 46% in those treated for acute rejection, and 28% in low
risk patients. By week 3 DNAemia was observed in 30% of patients who were not treated forcytomegalovirus infection/disease, and values ≥2.169 UI/mL showed 61% sensitivity and 85%
speciﬁcity to detect cytomegalovirus disease (AUC = 0.849 ± 0.042, p < 0.001). Using multivari-
ti-thymocyte globulin induction was associated with cytomegalovirusate analysis, only aninfection/disease whereas only expanded donor criteria and renal function at 30 days were
associated with renal function 12 months after transplantation.
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E-mail address: heliotedesco@medfarm.com.br (H. Tedesco-Silva Jr).
http://dx.doi.org/10.1016/j.bjid.2016.08.007
1413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
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Conclusion: Targeted preemptive therapy in patients with perceived higher risk for
cytomegalovirus infection/disease was effective in preventing severe clinical presentation,
including tissue invasive and late cytomegalovirus infection. This strategy is associated with
direct and indirect cost-savings.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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ytomegalovirus (CMV) infection remains one of the most
ommon complications affecting transplant recipients,1–3 and
as been associated with a wide spectrum of adverse events,
ncluding impaired graft function and occasional mortality.2
trategies for the prevention of CMV  infection have been asso-
iated with signiﬁcant reduction in incidence and severity of
isease.4,5 Despite the large variability in the management
f CMV  infection among transplant centers two main strate-
ies, namely universal prophylaxis or preemptive therapy, are
urrently used. Moreover, each of these strategies has signif-
cant variability in clinical practice, including the type of cell
r molecular diagnosis, antiviral therapies, frequency of mon-
toring, and criteria for initiating and stopping treatment.6
The incidence of CMV  infection is primarily associated
ith pretransplant serological status (donor positive, recipient
egative, D+/R−), use of induction with rabbit antithymocyte
lobulin (r-ATG), maintenance immunosuppressive regimen,
nd treatment for acute rejection.7–9 Although the use of
niversal prophylaxis has increased since the availability of
alganciclovir, there is still a debate related to the superior-
ty of this strategy over the preemptive approach.10–12 Data
rom prospective randomized trials have shown superiority
f prophylaxis over preemptive therapy only in the D+/R−
igh risk population. Moreover, the associated costs may be
 decisive factor in several countries with no pre-speciﬁed
eimbursement.13
One of the major concerns regarding preemptive therapy
s that it may not prevent the indirect effects of CMV infec-
ion, despite conﬂicting data on its association with graft and
atient survival.14–16 In addition, second episodes of CMV viral
eplication have been reported in up to 30% of patients, some
f which require further therapeutic intervention.17,18 On the
ther hand, in one recent study 53% of kidney transplant
ecipients receiving tacrolimus and mycophenolate presented
ransient CMV  viremia that was cleared spontaneously with-
ut anti-viral treatment.19
Considering these uncertainties, this study investigated
he use of targeted preemptive therapy for CMV infection
n a cohort of kidney transplant patients receiving different
mmunosuppressive regimens and no pharmacological CMV
nfection prophylaxis.
ethods
tudy  populationhis was a single center, prospective 12-month study in de
ovo kidney transplant recipients. The study was conductedlicenses/by-nc-nd/4.0/).
in compliance with Good Clinical Practice guidelines, in accor-
dance with the Declaration of Helsinki and was approved
by the local Ethics Committee. We screened patients older
than 18 years, recipients of ﬁrst or second kidney only trans-
plants from brain-dead deceased or living-related donors. All
patients signed an informed consent form.
Immunosuppression
Patients who received kidneys from expanded criteria
donors20 received induction therapy with 4 × 1.5 mg/kg doses
of r-ATG every other day from day 1 after transplantation. The
maintenance therapy consisted of 1440 mg  BID of mycophe-
nolate sodium. Tacrolimus (TAC) at initial dose of 0.05 mg/kg
BID was associated from day 7. TAC doses were adjusted to
maintain whole blood trough concentrations between 6 and
8 ng/mL during the ﬁrst three months and between 4 and
6 ng/mL thereafter.
Patients who received kidneys from standard deceased or
living donors received no induction therapy. The maintenance
therapy consisted of initial TAC doses of 0.1–0.15 mg/kg BID to
maintain whole blood trough concentrations between 10 and
15 ng/mL during the ﬁrst month and between 8 and 12 ng/mL
thereafter. Patients also received 1440 mg  BID of mycophe-
nolate sodium or azathioprine at daily doses of 2 mg/kg. All
patients received 1 g methylprednisolone prior to graft revas-
cularization and an initial 0.5 mg/kg of prednisone from day 1
tapered to 5 mg  by day 45.
Prophylaxis
No pharmacological prophylaxis for CMV infection was used.
All patients received oral trimethoprim-sulfamethoxazole for
at least six months as prophylaxis for Pneumocystis jiroveci
pneumonia or urinary tract infection, as per local practice. All
patients received albendazole 400 mg  for 5 days as prophylaxis
for parasitic infections.
CMV  management  strategy
Per local practice, only patients deemed high risk for CMV
infection were monitored for CMV  viral replication. High risk
patients were D+/R−, those who received induction ther-
apy with r-ATG, and those treated for acute rejection. These
patients were monitored every other week beginning on day
21 post transplant for CMV infection using the pp65 antigene-
mia  test. CMV infection in asymptomatic patients was deﬁned
as the presence of >10 pp65 positive cells/200,000 leucocytes.
CMV disease in symptomatic patients (fever, malaise, leukope-
nia, and/or thrombocytopenia) was deﬁned as the presence of
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Table 1 – Demographic characteristics of the study
population (n = 144).
Recipient
Age, years 46 ± 13
Gender, male 79 (55%)
Ethnicity
White 73 (51%)
Black 27 (19%)
Mixed 44 (30%)
Etiology of chronic kidney disease
Hypertension 24 (17%)
Diabetes 18 (12%)
Chronic glomerulonephritis 13 (10%)
Undetermined 61 (43%)
Other 28 (19%)
Time on dialysis, months 45 ± 48
Panel reactive antibodies, (%)
Class I 8.6 ± 2004 [0–89]
Class II 4.6 ± 17.2 [0–99]
Donor
Age, years 47 ± 13
Gender, male 77 (53%)
Ethnicity
White 84 (59%)
Black 15 (10%)
Mixed 45 (31%)
Type
Living 32 (22%)
Decease 112 (78%)
Standard 65 (56%)
Expanded criteria donor 47 (44%)
Cold ischemia time, hours 20 ± 6 (n = 112)
Transplant
CMV (IgG)
D+/R− 4 (3%)
D+/R+ 132 (92%)
D-/R+ 8 (5%)
HLA mismatches 2.4 ± 1.2
Induction therapy 56 (39%)
Immunosuppressive adjuvant drug
Mycophenolate 67 (46%)
Azathioprine 77 (54%)
CMV, cytomegalovirus; HLA, human leukocyte antigen; D, donor; R,
recipient.578  b r a z j i n f e c t d 
any pp65 positive cells/200,000 leucocytes. CMV  tissue inva-
sive disease was conﬁrmed by direct identiﬁcation of the
virus in any tissue. Treatment of CMV  infection or disease
consisted of intravenous 5 mg/kg BID ganciclovir, adjusted for
renal function. Treatment was monitored weekly with pp65
antigenemia test and extended for one additional week after
a negative antigenemia test.
Recurrence was deﬁned as the need for a new treatment
after complete remission of the last episode.
Quantitative  nucleic  acid  ampliﬁcation  test  (QNAT)
Patients were monitored for viral replication every week for
three months. Investigators were blinded to QNAT results.
CMV  DNAemia was quantiﬁed in EDTA human plasma sam-
ples using the COBAS® AmpliPrep/COBAS® TaqMan® CMV
test (Roche Molecular Diagnostics) according to manufacturer
instructions. The test allowed for determination of CMV DNA
ranging from 150 to 10,000,000 copies/mL. A copy of CMV  DNA
is equivalent to 0.91 International Units (IU) based on the 1st
WHO  International Standard for human CMV techniques for
nucleic acid ampliﬁcation.21
Efﬁcacy  and  safety
Delayed graft function was deﬁned as the need for at least
one dialysis during the ﬁrst week after transplantation. All
patients with suspected acute rejection underwent a core graft
biopsy and were classiﬁed according to Banff 2007 criteria.22
Treatment with methylprednisolone or r-ATG was consid-
ered according to clinical and histological severity analysis.
All corticosteroid-resistant acute rejection episodes were con-
ﬁrmed by biopsy and treated with r-ATG. Glomerular ﬁltration
rate (GFR) was calculated using the MDRD formula23 at 1 and
12 months.
Statistical  analysis
Descriptive analyses were summarized as mean and standard
deviation or proportions. Categorical variables were com-
pared using Chi-square test. Continuous variables were
compared using ANOVA test. Univariate and multivariate
logistic regression analyses were performed to identify risk
factors associated with CMV  infection/disease and with renal
function at 12 months. All statistical analyses were performed
using the SPSS 18 standard software (SPSS Inc., Chicago, IL,
USA) and differences were considered signiﬁcant at a p-value
<0.05.
Results
Of 155 screened patients, 144 patients were enrolled between
March 2013 and August 2013. Eleven patients were excluded
from this analysis, four due to missing donor CMV serologic
information, six received alternative immunosuppressive
regimens, and one was lost to follow up. Demographic charac-
teristics of the study population (n = 144) are shown in Table 1.
The majority of the patients tested positive for CMV  beforemean ± standard deviation; range in brackets.
transplantation (97%). Among high risk groups 3% were D+/R−
and 39% received induction therapy.
CMV  infection/disease
The overall incidence of ﬁrst CMV infection/disease was 51%
(73/144), 65% infection and 35% disease, with a global recur-
rence incidence of 23% (17/73), 71% (12/17) being recurrence
infection and 29% (5/17) recurrence of disease. None of the
patients developed tissue invasive disease. Mean time to ﬁrst
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Table 2 – Cytomegalovirus infection/disease.
First CMV event, n (%) Infection Disease Total
All patients, n = 144 48 (33%) 25 (17%) 73 (51%)
pp65+ cells 23 ± 52 [1–500] 16 ± 52 [2–139] 32 ± 51 [1–500]
Timing of the ﬁrst CMV event, days 42 ± 20 [19–128] 46 ± 22 [19–136] 43 ± 22 [19–136]
Treatment duration, days 22 ± 7 [14–35] 24 ± 8 [14–55] 22 ± 8 [14–55]
D+/R−, n = 4 1 (25%) 0 1 (25%)
pp65+ cells 5 5
r-ATG induction, n = 55 39 (71%) 7 (13%) 46 (84%)
pp65+ cells 15 ± 27 [1–119] 3 ± 1 [2–5] 14 ± 54 [1–119]
No induction and AZA, n = 74 5 (7%) 17 (23%) 22 (30%)
pp65+ cells 88 ± 61 [2–500] 34 ± 59 [2–139] 59 ± 58 [2–500]
No induction and MPS, n = 11 3  (27%) 1(9%) 4 (36%)
pp65+ cells 44 ± 82 [5–88] 1 [1] 32 ± 60 [1–88]
Without AR, n = 100 34 (34%) 19 (19%) 53 (53%)
pp65+ cells 12 ± 27 [1–44] 21 ± 28 [2–139] 15 ± 28 [1–139]
With AR, n = 44 14 (31%) 6 (14%) 20 (45%)
pp65+ cells 67 ± 63 [1–500] 32 ± 55 [2–75] 65 ± 54 [1–500]
CMV before AR episode 3 (6%) 0 3 (7%)
pp65+ cells 43 ± 30 [1–119] 30 ± 34 [1–119]
CMV after AR episode 11 (25%) 6 (14%) 17 (38%)
pp65+ cells 106 ± 75 [1–500] 32 ± 55 [2–75] 59 ± 54.6 [2–500]
Time after AR treatment, days 46 ± 31 36 ± 28 46 ± 32
Recurrent CMV events Infection Disease Total
All patients, n = 144 12 (8%) 5 (3%) 17 (11%)
pp65+ cells 24 ± 26 [2–119] 18 ± 15 [2–68] 22 ± 30 [2–119]
Timing after the ﬁrst CMV event, days 57 ± 21 84 ± 22 60 ± 19
Treatment duration, days 25 ± 9 24 ± 2 23 ± 9
Data are presented as mean ± standard deviation and range in brackets.
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CMV, cytomegalovirus; AR, acute rejection; r-ATG, rabbit anti-thymoc
MV  event and the duration of treatment were similar among
atients with infection or disease (Table 2).
Of the 73 ﬁrst episodes of CMV  infection/disease, 56 (77%)
ccurred in high risk patients during preemptive therapy
1 D+/R−, 38 who received induction therapy, and 17 after
reatment of acute rejection) and 17 (23%) in low risk patients
no induction, no D+/R−, no acute rejection) who had not
eceived preemptive therapy.
Of the four patients in the high-risk D+/R− group one
atient (25%) who also received induction therapy developed
MV  infection. Of the 55 R+ patients who received induc-
ion therapy 38 (69%) developed CMV  infection/disease before
ny treatment for acute rejection. Out of 37 patients treated
or acute rejection (11 received induction therapy) 17 (46%)
eveloped CMV  infection/disease, seven after treatment with
ethylprednisolone and 10 after treatment with methylpred-
isolone and r-ATG. The incidence of CMV infection/disease
fter treatment for acute rejection was higher among patients
ho  received induction therapy (8/11, 71%) compared to those
ithout induction therapy (9/26, 35%). In low risk patients (R+,
o induction, and no rejection), the incidence of CMV infec-
ion/disease was 28% (17/61).
There were 18 recurrent CMV  infection/disease episodes,
ith 16 patients presenting one and one patient presentingwo episodes. Recurrent episodes occurred in 14 patients
ho  received induction therapy (ﬁve were treated for acute
ejection before the ﬁrst CMV  episode) and in three patients
hat did not receive induction therapy but were treated forlobulin; AZA, azathioprine; MPS, mycophenolate sodium.
acute rejection before the ﬁrst CMV  episode. The number of
pp65 positive cells tended to be higher in patients with infec-
tion versus disease, in patients receiving no induction, and in
patients treated for acute rejection (Table 2).
CMV  viral  replication  by  QNAT
Data derived from blinded monitoring of CMV  viral load by
nucleic acid ampliﬁcation test is shown in Table 3. The cor-
relation between the number of pp65 positive cells and CMV
copies/mL is expressed by an r2 = 0.633 (p < 0.001). CMV viral
replication was initially detected by week 3 after transplan-
tation. High interindividual variability in CMV  DNAemia was
observed in patients developing CMV infection or disease.
DNAemia tended to be higher among patients with CMV dis-
ease compared to infection.
Among 71 patients who were not diagnosed with CMV
infection/disease based on pp65 antigenemia test, 50 did not
show any DNAemia and 21 (30%), 3 D+/R−, 8 who  received
induction therapy, 3 MPS and 10 AZA, presented asymp-
tomatic transient DNAemia with up to 9000 copies/mL during
the ﬁrst three months after transplantation (Table 3).
The receiver operating characteristic analysis
(AUC = 0.762 ± 0.037, p < 0.001) showed that CMV  DNAemia
≥722 UI/mL was associated with a sensitivity of 67% and
80% speciﬁcity to detect CMV infection diagnosed by pp65
antigenemia test. Likewise, the receiver operating character-
istic analysis (AUC = 0.849 ± 0.042, p < 0.001) showed that CMV
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Table 3 – CMV  viral replication by quantitative nucleic acid ampliﬁcation test (UI/mL).
Day N CMV-free (n = 71) N CMV infection (n = 48) N CMV disease (n = 25)
21 – 16 653 ± 963 [147–4072] 3 538 ± 418 [258–1021]
28 5 506 ± 591 [158–1557] 27 1888 ± 1718 [149–7087] 8 5982 ± 12,267 [203–36,205]
35 7 1289 ± 919 [151–2724] 26 5387 ± 17,289 [139–89,593] 10 25,780 ± 61,520 [171–196,783]
42 4 1714 ± 1615 [147–3782] 26 7997 ± 20,188 [142–81,382] 11 8814 ± 12,836 [142–43,063]
49 8 1749 ± 2872 [162–8389] 17 3047 ± 5901 [221–22,266] 10 22,660 ± 65,710 [422–208,038]
56 4 238 ± 75 [144–312] 5 1329 ± 1115 [242–2579] 7 67,694 ± 113,655 [225–251,383]
63 5 284 ± 171 [152–565] 13 2944 ± 6510 [155–23,399] 6 1970 ± 2968 [313–7874]
70 4 475 ± 478 [142–1181] 10 2393 ± 2548 [157–8400] 4 79,018 ± 153,062 [906–308598]
77 3 408 ± 261 [199–701] 10 1618 ± 1845 [220–5656] 3 210,663 ± 363,439 [769–630,327]
84 5 970 ± 1262 [157–3179] 12 3297 ± 649 [146–27,251] 9 1953 ± 808 [141–6713]
acketMean ± standard deviation (only values above 136 UI/mL); range in br
DNAemia ≥2.169 UI/mL was associated with a sensitivity of
61% and 85% speciﬁcity to detect CMV  disease diagnosed by
pp65 antigenemia test.
Efﬁcacy  and  safety
The incidence of ﬁrst treated biopsy conﬁrmed acute rejec-
tion was 26% and was higher among patients receiving AZA
compared to MPS.  Overall there were 48 treated acute rejec-
tion episodes, 3 graft losses, and 4 deaths during the ﬁrst
year after transplantation. Mean GFR at one month was
37.18 ± 19.73 ml/min with no difference comparing patients
with or without CMV infection/disease (39.19 ± 20.40 vs.
31.85 ± 17.17 ml/min, p = 0.158), respectively. At 12 months
mean GFR was lower in patients with CMV infection and/or
acute rejection compared to patients without these events
(Table 4).
Risk  factors  associated  with  CMV  infection/disease  and
renal  function  at  12  months
Donor age, expanded criteria donor, use of induction therapy,
use of MPS,  and renal function 30 days after transplanta-
tion were risk factors associated with CMV  infection/disease.
After multivariate analysis, only induction therapy remained
independently associated with CMV  infection/disease; renal
function at 30 days reached marginal signiﬁcance (p = 0.054)
(Table 5). Conversely, expanded criteria donor, time on dial-
ysis, D+/R−, use of induction therapy, use of MPS,  CMV
infection/disease, and renal function 30 days after trans-
plantation were risk factors associated with renal function
12 months after transplantation. After multivariate analysis,
only expanded donor criteria and renal function 30 days after
transplantation were independently associated with renal
function 12 months after transplantation (Table 6).
Discussion
This study described the incidence and risk factors for CMV
infection/disease in a cohort of kidney transplant recipients
receiving no pharmacological prophylaxis. Furthermore, pre-
emptive strategy was used only in patients deemed high risk
for CMV  infection/disease (D+/R−,  use of r-ATG induction
therapy, or after treatment of acute rejection). The overalls.
incidence of CMV infection was 34% and CMV  disease was
17% based on pp65 antigenemia. Importantly, of 73 patients
in the ﬁrst episode of CMV  infection/disease, 17 (23%) pre-
sented at least one recurrent event, but no episodes of tissue
invasive disease or late CMV infection (> 6 months) were
observed. A recent study showed 33% recurrence rate and
identiﬁed high viral load at initial diagnosis as independent
risk factor.24 In our cohort of patients peak DNAemia ranged
from 142 to 81.382 UI/mL during CMV infection and from 142
to 630.327 UI/mL during CMV disease.
The prevalence of the high risk D+/R− group (2.8%) was
lower compared to that observed in Europe or North America.
The incidence of CMV  infection/disease in this group was only
25%. Nevertheless, in one larger prospective trial including 288
patients with similar demographic characteristics and receiv-
ing only preemptive therapy, the prevalence of the high risk
D+/R− group was also low (5.2%), but the incidence of CMV
infection/disease was 63%.25
The incidence of CMV infection/disease was 84% in
patients receiving r-ATG induction therapy, conﬁrming the
results of previous studies.26,27 A recent meta-analysis showed
that the risk of developing CMV  infection/disease is 60% higher
in patients receiving r-ATG induction therapy.28 Other reviews
suggested that r-ATG induction therapy was associated with
increased incidence of CMV  infection/disease if prophylaxis
were not used29 or when compared with basiliximab in low
immunological risk patients.30
The incidence of CMV  infection/disease was 48% (37/77)
after treatment for acute rejection, conﬁrming the need
to restart preemptive therapy recommended by recent
guidelines.2 A recent study showed that acute rejection was
an independent risk factor associated with a 2.8-fold increased
risk for tissue-invasive CMV disease within six months of kid-
ney transplantation.31
On the other hand, in low risk patients (R+, no induc-
tion therapy, and no acute rejection) the incidence of CMV
infection/disease was 28%. Furthermore, 15% (21/144) of the
patients presented transient DNAemia (peak DNAemia ran-
ging from 162 to 8389 UI/mL) during the ﬁrst three months
after transplantation. In one study where patients were
treated only based on clinical suspicion, transient DNAemia
19was observed in 53% of the patients. DNAemia tended to
be higher in patients with disease compared to infection,
perhaps due to early treatment prompted by preemptive
therapy. All patients in this study were successfully treated
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Table 4 – Efﬁcacy parameters during the ﬁrst year after
transplantation.
Parameter Total (n = 144)
First treated BCAR 37 (26%)
Incidence in patients receiving MPS, n = 67 12 (18%)
Incidence in patients receiving AZA, n = 77 25 (32%)
Time after transplant, days 70 ± 91
Severity of the ﬁrst BCAR*
IA 18 (48%)
IB 18 (48%)
IIB 1 (4%)
Treatment of 1st BCAR
Methylprednisolone 27 (73%)
Methylprednisolone + anti-thymocyte globulin 10 (27%)
Patients with 2 treated acute rejection episodes 4
All treated acute rejection episodes 48
Severity of all treated acute rejection episodes*
Tubulointerstitial nephritis 2 (4%)
Borderline changes 9 (19%)
IA 18 (37.5%)
IB 18 (37.5%)
IIB 1 (2%)
Treatment of all acute rejection episodes
Methylprednisolone 38 (79%)
Methylprednisolone +anti-thymocyte
globulin
10  (21%)
Graft loss 3 (2%)
Death 4 (3%)
GFR at 12 months (ml/min)
All patients (n = 137) 52.87 ± 20.98
With CMV infection/disease (n = 68) 45.92 ± 17.87a
Without CMV infection/disease (n = 69) 58.46 ± 21.02
With acute rejection (n = 36) 47.09 ± 18.28b
Without acute rejection (n = 101) 54.92 ± 20.98
With CMV infection/disease and with acute
rejection (n = 20)
45.89  ± 16.27
With CMV infection/disease and without acute
rejection (n = 43)
45.98  ± 17.45
Without CMV infection/disease and with acute
rejection (n = 20)
46.72  ± 18.09
Without CMV infection/disease and without acute
rejection (n = 54)
62.76  ± 22.38c
BCAR, biopsy conﬁrmed acute rejection; MPS, mycophenolate
sodium; AZA, azathioprine; GFR, glomerular ﬁltration rate (MDRD
formula); *Banff (2007).
a p < 0.001, vs. without CMV infection.
b
w
d
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Op < 0.024, with vs. without acute rejection.
c p < 0.002, vs. with CMV infection and/or acute rejection.
ith ganciclovir and no ganciclovir resistant mutations were
etected. Therefore, none of these patients were treated with
oscarnet.1
Using receiver operating characteristic analysis the opti-
al  cutoff concentration for CMV  disease was 2.169 UI/mL,
hich is comparable to that observed in a cohort of CMV
eropositive solid organ transplant recipients (3983 UI/mL),32
n 97 liver transplant recipients (2000–5000 copies/mL),33nd in 102 D+/R+ kidney transplant recipients receiving
acrolimus, mycophenolate and prednisone (1920 IU/mL).19
n the other hand, higher cutoff values were proposed6;2 0(6):576–584 581
in other studies.34–36 This apparent discrepancy may be
due to differences in ethnic background, donor/recipient
pretransplant CMV serostatus, immunosuppressive regi-
mens used, biological sample (plasma versus blood), and
the QNAT used. This observation highlights the need to
validate locally the strategy used to monitor CMV  viral
replication.
The recurrence rate of CMCV infection in our cohort
of patients was 23% (17 of 73 patients with CMV infec-
tion/disease), which is lower than the 30% suggested in the
last consensus (2). Of these 17 recurrent episodes, 12 (71%)
were CMV  infection and 5 (29%) CMV disease, suggesting that
the preemptive strategy based on antigenemia test was ade-
quate. The option to trigger treatment earlier based on the
lower cutoff value of ≥722 UI/mL for CMV  infection is a mat-
ter of debate, considering the low proportion of patients with
CMV recurrence who ultimately developed disease and the
unnecessary treatment of those patients with low self-limited
viral replication. Individual assessment, based on CMV  viral
replication kinetics and more  frequent and prolonged moni-
toring is perhaps the ideal strategy, considering that recurrent
episodes were diagnosed up to 106 days after completion of
ﬁrst treatment.
Among recognized risk factors associated with CMV
infection/disease after transplantation, r-ATG induction was
associated with an almost 8-fold increased risk compared
to no induction. The representation of the high risk D+/R−
group was too small to detect an association with CMV infec-
tion/disease. Interestingly, renal function at the end of the ﬁrst
month after transplant was associated with 2-times higher
risk of development of CMV infection/disease. In a recent
study, the prevalence of interstitial ﬁbrosis and tubular atro-
phy at six weeks after transplantation was 3-fold higher in
patients who experienced CMV infection later-on, compared
to patients without CMV.37 In this study only a small difference
in GFR measured at six weeks was observed comparing patient
with or without CMV (57 ± 23 vs. 61 ± 23 ml/min; p = 0.083),
similar to our observation.
Finally, it has been suggested that CMV  infection/disease
and acute rejection are associated with reduced renal
function.1,38 In our cohort we  were unable to ﬁnd an inde-
pendent association between CMV infection/disease or acute
rejection and renal function at the end of the ﬁrst year after
transplantation. Instead, only expanded criteria donor and
renal function at the end of ﬁrst month were associated with
inferior renal function at 12 months.
This study has some limitations, including the relative
small sample size, low representation of the high risk D+/R−
group, short follow up, unique demographic characteristics of
the study population and immunosuppressive strategies used
in a single center, and the ﬁndings may not be directly extrap-
olated to other kidney transplant recipients.
Strategies to manage CMV  infection are evolving despite
the growing use of universal prophylaxis. The high inci-
dence of transient spontaneously resolved asymptomatic
CMV viremia, the costs and adverse events associated with
universal prophylaxis and late CMV infection after its dis-
continuation, and the uncertainties of the effect of CMV
DNAemia on graft and patient outcomes are the driving rea-
sons for the continued search for alternative strategies. Our
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Table 5 – Risk factors associated to CMV  infection/disease during the ﬁrst year after kidney transplantation.
Covariates Univariable analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Donor
Age, years [18–74] 1.104 1.002 1.217 0.046
Expanded criteria donor, yes 5.922 2.688 13.049 0.000 0.807 0.184 3.546 0.777
Recipient
Recipient age [18–73] 0.937 0.853 1.028 0.168
Gender, male 0.794 0.412 1.534 0.508
Body mass index, kg/m2 [16–37] 0.956 0.778 1.174 0.666
Time on dialysis, months [1–220] 1.008 0.985 1.031 0.503
PRA Class I [1–89] 0.969 0.924 1.016 0.189
PRA Class II [4–99] 1.031 0.988 1.075 0.157
Transplant
Cold ischemia time, min [17–2140] 1.000 0.998 1.002 0.947
HLA mm [0–6] 1.194 0.556 2.564 0.648
D+/R− CMV, yes 3.176 0.323 31.283 0.363 1.803 0.106 30.810 0.684
Delayed graft function, yes 1.323 0.687 2.548 0.411 0.924 0.409 2.085 0.848
Induction therapy, thymoglobulin 12.453 5.336 29.063 0.000 7.687 1.688 35.001 0.008
Antimetabolite, MPS 7.969 3.771 16.840 0.000 1.914 0.392 9.345 0.422
Acute rejection, yes 1.199 0.567 2.536 0.705 1.801 0.727 4.463 0.204
Repeated acute rejection, yes 1.277 0.391 4.167 0.769
GFR at 30 days, <45 ml/min 3.533 1.779 7.017 0.000 2.212 0.986 4.964 0.054
CMV, cytomegalovirus; HR, hazard ratio; CI, conﬁdence intervals; PRA, panel reactive antibodies; HLA mm, histocompatibility leukocyte antigen
mismatch; D, donor; R, recipient; MPS, mycophenolate sodium; GFR, glomerular ﬁltration rate.
Table 6 – Risk factors associated with inferior renal function (GFR< 51.7 ml/min) one year after kidney transplantation.
Covariates Univariable analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Donor
Age, years [18–74] 0.994 0.907 1.090 0.904
Expanded criteria donor, yes 2.778 1.326 5.817 0.008 4.707 1.185 18.690 0.028
Recipient
Age, years [18–73] 1.049 0.946 1.161 0.364
Gender, male 0.807 0.416 1.564 0.614
Body mass index, kg/m2 [16–37] 0.709 0.483 1.041 0.709
Time on dialysis, months [1–220] 0.962 0.925 0.999 0.045
PRA Class I [1–89] 0.985 0.941 1.031 0.516
PRA Class II [4–99] 1.004 0.971 1.038 0.806
Transplant
HLA mm [0–6] 0.456 0.196 1.062 0.069
D+/R = CMV, yes 2.333 1.927 2.825 0.037
Cold ischemia time min [17–2140] 1.001 0.998 1.003 0.633
Delayed graft function 0.808 0.418 1.561 0.615 0.765 0.350 1.675 0.503
Induction therapy, thymoglobulin 2.630 1.297 5.333 0.010 3.274 0.525 20.408 0.204
Antimetabolite, MPS 1.937 0.991 3.786 0.065 1.040 0.120 8.660 0.360
Acute rejection, yes 0.594 0.280 1.260 0.185 0.518 0.206 1.301 0.161
Repeated acute rejection, yes 0.969 0.299 3.139 1.00
CMV infection/disease, yes 2.634 1.339 5.185 0.007 1.510 0.603 3.782 0.379
GFR at 30 days, <45 ml/min 7.792 3.710 16.365 0.000 7.696 3.389 17.473 0.000
, pane
lar ﬁCMV, cytomegalovirus; HR, hazard ratio; CI, conﬁdence intervals; PRA
mismatch; D, donor; R, recipient; MPS, mycophenolate; GFR, glomeru
data suggests that targeted preemptive therapy in patients
with perceived higher risk for CMV  infection/disease (D+/R−,
use of r-ATG, treatment of acute rejection) is effective in
preventing severe clinical presentation, including tissue inva-
sive and late CMV  infection. Furthermore, substitution ofl reactive antibodies; HLA mm, histocompatibility leukocyte antigen
ltration rate.
azathioprine and mycophenolate by mTOR  inhibitors may
further reduce the incidence and recurrence of CMV  infec-
tion in patients receiving no pharmacological prophylaxis.
Eventually, monitoring of CMV viral replication will be per-
formed only in high risk patients and in those discontinuing
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he use of mTOR  inhibitors.25 These effective strategies are
ssociated with direct and indirect cost-savings and reduced
se of human resources.
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